Literature DB >> 2925573

Naltrexone in autistic children: an acute open dose range tolerance trial.

M Campbell, J E Overall, A M Small, M S Sokol, E K Spencer, P Adams, R L Foltz, K M Monti, R Perry, M Nobler.   

Abstract

The safety and efficacy of naltrexone was explored in an open acute dose range tolerance trial in 10 hospitalized autistic children, ages 3.42 to 6.50 years (mean, 5.04). Naltrexone was given in ascending doses: 0.5, 1.0, and 2.0 mg/kg/day. Behavioral side effects were observed as early as 1/2 hour after dosing. Ratings on the Children's Psychiatric Rating Scale showed that withdrawal was reduced across all three dose levels; administration of 0.5 mg/kg/day dose resulted in increased verbal production; and the 2.0 mg/kg/day dose resulted in reduction of sterotypies. Mild sedation of brief duration was the only side effect. Electrocardiogram, liver function tests, and all other laboratory studies remained unchanged throughout the study. These preliminary findings require replication in a larger sample of patients under double-blind and placebo controlled condition.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2925573     DOI: 10.1097/00004583-198903000-00009

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  10 in total

Review 1.  Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders.

Authors:  M G Aman; K S Langworthy
Journal:  J Autism Dev Disord       Date:  2000-10

2.  Brief report: a double-blind study of naltrexone in infantile autism.

Authors:  M Leboyer; M P Bouvard; J M Launay; F Tabuteau; D Waller; M Dugas; B Kerdelhue; P Lensing; J Panksepp
Journal:  J Autism Dev Disord       Date:  1992-06

3.  Brief report: plasma beta-endorphin and cortisol levels in autistic patients.

Authors:  C A Sandman; J L Barron; A Chicz-DeMet; E M DeMet
Journal:  J Autism Dev Disord       Date:  1991-03

4.  Brief report: a synopsis of an open-trial of naltrexone treatment of autism with four children.

Authors:  J Panksepp; P Lensing
Journal:  J Autism Dev Disord       Date:  1991-06

Review 5.  Opiate antagonists in children and adolescents.

Authors:  N Chabane; M Leboyer; M C Mouren-Simeoni
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

6.  Oxytocin under opioid antagonism leads to supralinear enhancement of social attention.

Authors:  Olga Dal Monte; Matthew Piva; Kevin M Anderson; Marios Tringides; Avram J Holmes; Steve W C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-01       Impact factor: 11.205

Review 7.  Advances in drug treatments for children and adolescents with autism and other pervasive developmental disorders.

Authors:  Richard P Malone; Silvia S Gratz; Mary Anne Delaney; Susan B Hyman
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

8.  A case report of naltrexone treatment of self-injury and social withdrawal in autism.

Authors:  A S Walters; R P Barrett; C Feinstein; A Mercurio; W T Hole
Journal:  J Autism Dev Disord       Date:  1990-06

Review 9.  Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders.

Authors:  Michael G Aman; Cristan A Farmer; Jill Hollway; L Eugene Arnold
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2008-10

10.  Autism Case Report: Cause and Treatment of "High Opioid Tone" Autism.

Authors:  Vishal Anugu; John Ringhisen; Brian Johnson
Journal:  Front Psychol       Date:  2021-05-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.